NY-INNOVATIVE-HEALTH
Innovative Health Sciences, LLC (“IHS” or the “Company”) announced today that they have received ISO 13485 quality management system and CE mark certification for the Insignis™ Syringe Infusion System. The CE mark, abbreviated for European Conformity ("Conformité Européene"), enables IHS to sell the system throughout the European Union.
The Insignis™ Syringe Infusion System is the first combination of intravenous and subcutaneous non-electric infusion pump created for use with a selectable rate flow controller, the IV Controller and the OneSett™.
The transformative Insignis™ System for intravenous administration answers the world-wide need for a portable, non-electric, versatile, cost-effective, and intuitive infusion pump to accurately deliver medications from KVO up to 250ml/hr with a direct reading selectable rate flow controller.
For subcutaneous applications, the OneSett™ consists of a selectable rate flow controller attached directly to a subcutaneous needle set (1-4 leg configuration offering), which enables the user to select the flow rate (from 10ml – 60ml) with the turn of a dial. The flow rate indicated on the dial is delivered to each needle site – no calculation required!
The Insignis™ syringe pump is much less costly, offered at 139 Euro, and when considering the cost of the separate pieces of the ancillary supplies (needle sets, flow control tubings, and flow controller), the OneSett™ is also lower cost per infusion – even before considering the savings incurred from fewer stocking parts.
The IHS infusion system addresses nearly every infusion therapy need and can support intermittent, “pause” dosing, ideal for lengthy low-volume hospital infusions. “The IHS system represents a paradigm shift in simplicity, excellence, cost effectiveness, usability and patient-centered design,” says Andrew Sealfon, IHS founder, Chairman, and CTO.
Sealfon is a forty-year investor, innovator, and executive of the medical device industry. Inventor and founder of Repro-Med Systems, Inc. (KORU Medical Systems), Sealfon served as its President, Chairman of the Board, and Chief Executive Officer from September 1982 until his termination (July 25, 2018).
About Innovative Health Sciences
New York-based Innovative Health Sciences, LLC provides innovative solutions to the infusion healthcare market. IHS’ approach is patient-centric and future-oriented; our goal is to provide the highest quality of life by empowering the patient to take control of their infusion.
Forward-Looking Statements
The statements contained herein are not guaranteed of future performance and undue reliance should not be placed on them. Such Forward-Looking Statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied. These statements are based on management’s beliefs and theory. The Company undertakes no obligation to update Forward-Looking Statements if circumstances or management’s estimates or opinions should change, except as required by applicable securities laws.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210722005313/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Uptime Institute Announces Five Data Center Predictions Report for 202613.1.2026 12:04:00 CET | Press release
As corporate AI moves beyond pilots and experimentation, infrastructure designers and operators face a series of big challenges spanning power, resiliency, sustainability and automation Uptime Institute today announced the release of its Five Data Center Predictions for 2026 looking beyond the more obvious trends of 2026 and examining some of the latest developments and challenges shaping the digital infrastructure industry. The 2026 predictions focus on the continued growth of the industry and related challenges, while also recognizing AI as a powerful, transformative accelerant to growth. While AI is the key driver for a wave of investment that will underpin digital infrastructure for decades to come, the speed and ultimate size of the build-outs are unclear at this time. “Critical digital infrastructure continues to expand strongly,” said Andy Lawrence, Executive Director of Research, Uptime Institute. “At the same time, our research shows uncertainty about how AI will reshape deman
BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference13.1.2026 12:00:00 CET | Press release
Company outlines foundational hematology leadership, multiple 2026 data catalysts, a unique global clinical development superhighway, and continued financial excellence BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will outline the pillars of its growing global oncology leadership during its presentation today at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. John V. Oyler, Co-Founder, Chairman, and CEO at BeOne, will highlight the Company’s transformative leadership in treating B-cell malignancies. The presentation will feature BRUKINSA®, the global leader among Bruton’s tyrosine kinase (BTK) inhibitors, as well as foundational hematology assets: sonrotoclax, a next-generation and potentially best-in-class B-cell lymphoma 2 (BCL2) inhibitor that received its first global regulatory approvals on December 30, and BGB-16673, a potentially first-in-class and best-in-class BTK chimeric degradation activation compound (CDAC). I
BlueMatrix and Perplexity Partner to Bring AI-Powered Discovery to Institutional Research13.1.2026 12:00:00 CET | Press release
Partnership enables AI-assisted research while preserving BlueMatrix’s governance-first approach to integrating AI into regulated research environments. BlueMatrix, the global leader in capital markets content publishing technology, backed by Thoma Bravo, today announced a partnership with Perplexity to bring AI-enabled research and discovery to institutional investors using BlueMatrix’s governed, entitlement-aware framework. The partnership brings entitled broker research to Perplexity Enterprise users, enabling buy-side professionals to query their subscribed research content, alongside Perplexity’s broader capabilities, including real-time financial data, earnings transcripts, and deep research tools. Investment professionals and researchers can use natural language to surface relevant insights without changing existing data ownership, entitlements, or compliance structures. As buy-side teams increasingly turn to AI tools for research synthesis, a formal integration through BlueMatr
Vaudoise Becomes First Swiss Insurer to Go-Live with Guidewire Cloud Platform13.1.2026 11:21:00 CET | Press release
Vaudoise and Guidewire (NYSE: GWRE) have announced that Vaudoise has become the first Swiss insurer to go-live on Guidewire Cloud Platform. The company has successfully implemented Guidewire ClaimCenter and is currently integrating Guidewire PolicyCenter. By adopting Guidewire Cloud Platform, Vaudoise joins a global community of insurers focusing on insurance excellence with core modernization from a scalable, secure and rapidly updatable cloud delivery model. Arno Suess, Head of P&C Claims at Vaudoise, said: “We are very proud of this milestone, which sets a new benchmark for our industry. With Guidewire Cloud Platform, we can now process motor insurance claims faster, with greater automation and fully digital processes. The result: faster decisions, more transparency, and a seamless experience for customers during critical moments in their lives.” Mathias Grobet, EMEA VP at Guidewire, said: “Vaudoise is well-known for its customer focus, operational excellence and agility – qualities
Ant International Powered Over 2 Billion Transactions in its Core Emerging Markets in 2025, Expanding AI Payments and Digital Commerce Tools for Inclusive Growth13.1.2026 11:15:00 CET | Press release
150 million merchants across the world from Kuala Lumpur to London leverage Ant International’s solutions to reach local and global customers.In its main emerging markets, clients in Southeast Asia, South Asia, the Middle East and Latin America, including the SME sectors, recorded strong uplift through digital payments, cross-border commerce and banking solutions in 2025. Ant International supported over 2 billion digital cross-border transactions in 2025 for merchants in its core emerging markets including Southeast Asia (SEA), South Asia, the Middle East and Latin America (LATAM), as the company builds out a broader range of AI-powered digital financial and commerce solutions tailored to these regions’ diverse needs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113850175/en/ Alipay+ now connects more than 1.8 billion user accounts across 40 international payment partners to merchants across more than 100 markets Ant I
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom